Route one
Small-molecule readthrough
Six drugs are predicted, but their uncertainty intervals overlap almost everywhere. They cannot be ranked honestly.
Predicted, but not separable
Nonsense variants and the therapies aimed at them
A nonsense variant stops a protein early. RiboRescue compares three rescue routes—and shows where the evidence runs out.
The problem
Genes are read in three-letter codons. A nonsense variant turns an amino-acid codon into an early stop.
protein builtpremature stopnever built
The cell may also destroy the message. A therapy therefore needs both surviving RNA and readthrough.
The three routes
One route is uncertain, one unvalidated, and one geometrically decidable.
Route one
Six drugs are predicted, but their uncertainty intervals overlap almost everywhere. They cannot be ranked honestly.
Predicted, but not separable
Route two
A custom adapter restores one amino acid at one stop. Public data do not yet validate it.
Designable, but unvalidated
Route three
DNA-letter geometry is decidable from sequence: 22,042 of 70,660 scoreable variants are reachable.
Decidable from sequence
Where to go
Each page answers one question, keeps its denominator, and avoids a composite treatment score.
The instrument
Six checks on real ribosomes—including a failed hypothesis.
One variant
Four evidence layers for one stop.
The landscape
Three rescue routes across 70,376 variants.
The cost side
G418 measured where readthrough is unwanted.
The gaps
Five experiments for the unanswered questions.
The build
Decisions, failures, and what survived.